

# Chapter 1

## A Taxonomy of Problems

The term “data science” has been overused in recent years, and it has become something of a buzzword as a result<sup>1</sup>. However, I think it can best be described as:

**data science:** Any endeavor in which statistics, machine learning, data analysis, computer science, and information science intersect with domain knowledge.

Data science is about using the machinery of statistics and computer science to solve real-world problems. In the clinical domain, that means incorporating methods from epidemiology, biostatistics, computer science, and machine learning with insights gained from the clinical research literature and the practical experiences of physicians, nurses, hospital administrators, operational teams, and biomedical researchers.

### 1.1 Project Examples

Whenever I teach, I ask students to provide some examples of projects for which they think data science could be useful. The following are real examples. They provide a broad representation of most of the types of problems clinicians and health system operations/population health teams are interested in.

---

<sup>1</sup>See also: “artificial intelligence”, “machine learning”, “deep learning”.

1. *Unnecessary ER trips.* “Given a number of factors (types of admissions a person has had in the past, number of admissions/re-admissions, social determinants, etc.) can we predict who is going to show up at the emergency room unnecessarily”
2. *Good/poor candidates for program.* “determine if patients are good or poor candidates for one of our specialty care model bundle programs”
3. *Predicting unplanned admissions.* “predicting unplanned inpatient admissions based on many different variables (e.g. chronic conditions, engagement with primary care, etc.) and how these inputs interact with each other”
4. *Recommending an intervention.* “...stratification/prioritization of care management or other interventions or for clinical decision support... a tool would recommend an appropriate intervention based on the profile of the patient”
5. *Recommending a diagnosis.* “Based on unstructured chat conversations and also structured questions/forms/data... map out possible care pathways. For example, if someone says they have stomach pain, gives their zip code, insurance, pain tolerance and symptoms, and is logged in so we have past history, ask a few more questions and then we could determine they are 45% likely to have ulcer vs. constipation vs. food poisoning vs. appendicitis.”
6. *Predicting the amount paid by patients.* “Patient bill estimates - learning from claims data typical amount paid by patients for appointment reasons/types (e.g. estimate of additional services/care administered, and associated cost, based on patient details such as age, gender, etc.)”
7. *Identifying patient subtypes.* “identify cohorts within a population with chronic conditions based on their differences in longitudinal care across the continuum of settings (inpatient, ambulatory, primary care, specialty care, etc.)”
8. *Which conversations are similar?* “using previous chat histories to train (a chatbot) and become more effective/efficient for different, future patient chat experiences”

9. *Predictors of COVID-19 outcomes.* “Get baseline diabetes control marker (HbA1C) and acute glycemic control (inpatient glucose values) and see if either is a stronger predictor of COVID-19 outcomes (ICU, intubation, death).”
10. *Factors influencing mortality in myelofibrosis.* “We see lots of patients who are ineligible for clinical trials based on comorbidities and underlying organ dysfunction. However it is unclear how these factors affect OS. I would like to extract comorbidity data and baseline laboratory factors in patients with myelofibrosis to see how these factors affect mortality, if controlled for such important factors such as treatment, age, sex, insurance, number of comorbidities, and clinical risk score (DIPSS).”
11. *Non-adherence and difficult-to-treat asthma.* “We want to see whether non-adherence to prescribed inhaled corticosteroids plays a major role in poorly controlled asthma. Difficult-to-treat asthma can be evaluated by the number of ED visits, hospitalizations, prescriptions of prednisone and prescriptions of biological therapies. Using EPIC [we] can obtain medicine reconciliation information, of prescriptions sent, what proportion of those prescriptions were dispensed by Pharmacy. Question is can we find associations between the percentage of prescriptions filled and difficult-to-treat asthma.”
12. *Impact of diabetes and hyperglycemia on progression-free survival.* “Aim: Assess the impact of diabetes and hyperglycemia on first-line systemic therapy response (progression-free survival) in patients with advanced non-small cell lung cancer. Diabetes- defined by presence of diagnosis codes coding for diabetes. Hyperglycemia- random glucose >200 ng/dL. Co-variates of interest- age, sex, other treatments (RT, surgery), malignancy characteristics (stage, histology), smoking history, ecog (performance status), comorbidities, medications (steroids, anti-hyperglycemics)”
13. *Effect of statin use on MACE.* “Retrospective cohort study in elderly patients with CAD taking statins...exposed group are patients on a high-intensity statin; control group are patients on a moderate- or low-intensity statin. Participants matched based on age, gender, LDL category, and Elixhauser index category... The primary efficacy outcome

would be the time-to-first-event of 3-point MACE<sup>2</sup>.”

14. *Clustering patients with NAFLD*. “We wanted to understand non-alcoholic fatty liver disease (NAFLD) better, so we developed a cohort of NAFLD patients using EMR-based criteria and then clustered them based on comorbidities, medications, vital signs, and lab values to identify NAFLD subtypes. We then characterized the phenotypes and outcomes of the different subtypes.”

## 1.2 Abstracting the Problem

All of these examples describe situations where we want to use data to answer questions of clinical or operational importance. While the details differ in each scenario, the important thing to notice here is that many of the tasks themselves are structurally similar.

For example, all of the items except 7 – 8 and 14 describe situations where we want to associate information about a patient with a particular outcome or recommendation. Using information about a patient to estimate the size of a bill (#6) may appear to be a very different problem than uncovering factors influencing myelofibrosis mortality (#10), but the structure of the two problems is similar: the patient features are used as input, and the output is whatever quantity you care about (e.g. the cost to the patient in dollars or the probability of mortality by a certain timepoint).

Learning to see these types of similarities will give you a tremendous amount of power when attacking new problems in clinical data science. It will allow you to confidently deploy methods you used to solve one problem on a wide range of other problems. Each new method you learn then multiplies your capacity to solve problems, rather than adding to it.

### Question 1.1

How are items 7 – 8 and 14 different from the rest?

---

<sup>2</sup>MACE stands for “Major Adverse Cardiac Event”. The 3-point MACE is a composite of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.

#### Question 1.2

How are items 1 – 6 similar to items 9 – 13 and how are they different?

#### Question 1.3

How do items 1 – 3 differ from items 4 – 5 and how are they similar?

#### Question 1.4

How do items 1 – 3 differ from item 6? How is item 6 different from all of the other items?

#### Question 1.5

How do items 9 – 11 differ from items 12 – 13?

## 1.3 Terms and Contrasts

The basic ways in which clinical data science problems vary can be characterized using a few broad conceptual distinctions. These draw from both traditional clinical disciplines, like epidemiology, as well as machine learning/statistics.

### 1.3.1 Guidance vs. Understanding

Before beginning any study, it is important to carefully consider the study's goal and how the findings from the study will be used. This will help guide you in choosing appropriate methods. For example, in some studies we care mainly about using data to provide **guidance** that will enable us to perform our jobs better in the future. We may want to predict whether a patient is likely to experience an adverse outcome, or we may want to learn the type of patient who is most likely to benefit from a particular treatment. In these cases, we want the data to guide us in making better choices.

Now, contrast this with a study whose primary goal is scientific **understanding**. In this case, we care more about using data to improve our understanding of a phenomenon than in operationalizing those findings. For example, we may be interested in whether a particular genetic variant affects a phenotype, or we may want to establish a causal link between a particular treatment and an outcome.

The distinction is fuzzy and often imperfect, and the same kinds of methods can often be used in both cases. Depending on the goal, however, one may be willing to make certain compromises. For example, complex, “black box” predictive models (e.g. deep learning models) may be appropriate when the goal is guidance, but offer little in the way of understanding. Conversely, regression models have become the de facto standard for clinical trials and causal inference, but may not lead to optimal predictive ability. In situations where the primary goal is a rigorous understanding of causal relationships, that may not matter as much.

### 1.3.2 Observational Study vs. Experiment

In **experimental studies**, the investigator manipulates some aspect of the subjects’ experience and studies its effect on the outcome of interest. For example, here is the NIH’s definition of a **clinical trial**:

A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.


A clinical trial, therefore, is an experiment, because we control the intervention and monitor the effect of that intervention on one or more outcomes. Usually experimental studies employ some type of **randomization** to ensure that comparisons between different intervention groups are fair.

An **observational study**, in contrast, makes no attempt to interfere with its subjects. Instead, these individuals are simply observed, and inferences are made about the associations between different parameters and the outcome(s). Observational study designs and analytic plans are carefully designed to

minimize the effects of different sources of bias that can creep in due to lack of randomization. Although they're not usually referred to using this terminology, virtually all "big data" and machine learning oriented studies in healthcare are observational studies, because they use large datasets that were collected for other purposes.

### 1.3.3 Types of Machine Learning

This distinction, most often found in discussions of machine learning, refers to the way in which training data is applied to solve a problem. In **supervised learning**, the training data consist of pairs of input features and labels, and the algorithm learns to predict the value of the label from the input features. The general setup for supervised learning looks like this:



In **unsupervised learning**, only the input features are present (i.e. no  $y$ ) and the algorithm learns to recognize patterns, clusters, or other structure in the inputs. Although they're almost never referred to using this terminology, clinical studies that examine the effect between one or more exposures and an outcome are examples of supervised learning. Studies that attempt to uncover groups, or clusters, of similar patients or samples are examples of unsupervised learning.

There are also two other types of machine learning. In **semi-supervised learning**, a small amount of labeled data is used to create a much larger,

weakly-labeled set of training data that is then fed to a supervised learning algorithm. In **reinforcement learning**, an algorithm is trained with a reward system which provides feedback on the quality of the action the system performs in a given situation instead of (as in supervised learning) simply providing the “right answer”.